Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of INCB057643 as monotherapy or combination with ruxolitinib for participants with myelofibrosis (MF) and other myeloid neoplasms.
Myelofibrosis|Myelodysplastic Syndrome|Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome|Myeloproliferative Neoplasm|Relapsed or Refractory Primary Myelofibrosis|Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis)|ET (Essential Thrombocythemia)
DRUG: INCB057643|DRUG: Ruxolitinib
Number of treatment-emergent adverse events, Defined as adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug monotherapy and in combination with ruxolitinib., Up to approximately 9 months
Spleen Volume Response, Defined as achieving a protocol defined reduction at Week 24 relative to baseline as measured by MRI or CT scan., Week 24|Duration of a Spleen Volume Response from baseline (MF only), Defined as the interval between the first spleen volume response and the date of the first measurement that no longer achieves the protocol defined criteria., Up to approximately 9 months|Symptom Response Rate (MF or ET), Defined as the proportion of participants who achieve a protocol defined reduction in Total Symptomatic Score (TSS) relative to baseline as measured by the MPN-symptom assessment form (SAF) TSS., Week 24|Anemia Response (MF only), A hemoglobin increase of 1.5 g/dL relative to baseline for any "rolling" 12-week period during the study treatment period, if transfusion independent (TI) at baseline or Achieving TI for any "rolling" 12-week period during the study treatment period, if transfusion dependent (TD) at baseline., Up to approximately 9 months|Duration of Anemia Response (MF only), The interval from the first onset of anemia response to the earliest date of loss of anemia response that persists for at least 4 weeks or death from any cause for the TI participants at baseline or duration of RBC-TI period for participants achieving RBC-TI for at least 12 consecutive weeks during the study treatment period for the TD participants at baseline., Up to approximately 9 months|Changes in hemoglobin value from baseline (MF only), Defined as the mean change from baseline in the hemoglobin value over 12-week treatment periods., Up to approximately 9 months|Red Blood Cell (RBC) Transfusion Burden (MF only), Defined as the average number of RBC units per participant-month through Weeks 12, 24, and 48., Up to approximately 9 months|Overall response (ET only), Defined as proportion of participants with complete response or partial response and hematological improvement/response as per definition for ET., Up to approximately 9 months|Duration of platelet count reduction or White Blood Cell (WBC) count reduction (ET only), Defined as platelet count reduction or WBC count reduction lasting â‰¥ 12 weeks., Up to approximately 9 months|Bone Marrow (BM) Blast Complete Remission (MF, myelodysplastic syndrome (MDS), and MDS/myeloproliferative neoplasm (MPN)), Defined as BM blasts achieving the protocol defined criteria., Up to approximately 9 months|BM Blast Partial Remission (MF, MDS, and MDS/MPN), Defined as BM blasts achieving the protocol defined criteria., Up to approximately 9 months|Peripheral Blast Complete Remission (MF, MDS, and MDS/MPN), Defined as peripheral blasts achieving the protocol defined criteria., Up to approximately 9 months|Peripheral Blast Partial Remission (MF, MDS, and MDS/MPN), Defined as peripheral blast achieving the protocol defined criteria., Up to approximately 9 months|Durable Blast Complete or Partial remission (MF, MDS, and MDS/MPN), Defined as achieving the protocol defined criteria., Up to approximately 9 months
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of INCB057643 as monotherapy or combination with ruxolitinib for participants with myelofibrosis (MF) and other myeloid neoplasms.